In a report released today, Difei Yang from Mizuho Securities maintained a Buy rating on Xeris Pharmaceuticals (XERS), with a price target of $14.00. The company’s shares closed last Thursday at $4.92.
According to TipRanks.com, Yang is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -5.8% and a 34.7% success rate. Yang covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Akebia Therapeutics, and Nektar Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Xeris Pharmaceuticals with a $14.00 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $7.16 and a one-year low of $1.42. Currently, Xeris Pharmaceuticals has an average volume of 1.67M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Xeris Pharmaceuticals, Inc.is a pharmaceutical company, which develops and commercializes ready-to-use, liquid-stable injectables. It offers XeriSol™ and XeriJect™ formulation technologies. The company was founded by Steven Prestrelski and John Kinzell in 2005 and is headquartered in Austin, TX.
